ID: ALA3703707

Max Phase: Preclinical

Molecular Formula: C21H20N6O

Molecular Weight: 372.43

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1cc(-c2n[nH]c3cc(NC(=O)NCCc4ccccc4)ncc23)ccn1

Standard InChI:  InChI=1S/C21H20N6O/c1-14-11-16(8-10-22-14)20-17-13-24-19(12-18(17)26-27-20)25-21(28)23-9-7-15-5-3-2-4-6-15/h2-6,8,10-13H,7,9H2,1H3,(H,26,27)(H2,23,24,25,28)

Standard InChI Key:  SXHJFLZPXBCHPC-UHFFFAOYSA-N

Associated Targets(non-human)

Mapk1 MAP kinase ERK2 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 372.43Molecular Weight (Monoisotopic): 372.1699AlogP: 3.69#Rotatable Bonds: 5
Polar Surface Area: 95.59Molecular Species: NEUTRALHBA: 4HBD: 3
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.38CX Basic pKa: 4.77CX LogP: 2.76CX LogD: 2.76
Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.50Np Likeness Score: -1.48

References

1.  (2015)  Compounds that are ERK inhibitors, 
2. Lim J, Kelley EH, Methot JL, Zhou H, Petrocchi A, Chen H, Hill SE, Hinton MC, Hruza A, Jung JO, Maclean JK, Mansueto M, Naumov GN, Philippar U, Raut S, Spacciapoli P, Sun D, Siliphaivanh P..  (2016)  Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.,  59  (13): [PMID:27329786] [10.1021/acs.jmedchem.6b00708]